| Analysis | Metabolite Name | Measured Value | Units | Gender | Glycemic status | Neuropathy |
|---|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 1214780 | Peak area normalized | male | Pre-diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 1701049 | Peak area normalized | female | Pre-diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 1873723 | Peak area normalized | female | Diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 2141471 | Peak area normalized | female | Pre-diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 2395833 | Peak area normalized | male | Diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 2442565 | Peak area normalized | male | Normoglycemic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 2472244 | Peak area normalized | female | Pre-diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 2542751 | Peak area normalized | female | Pre-diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 2946661 | Peak area normalized | male | Normoglycemic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 2971503 | Peak area normalized | male | Normoglycemic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 3029679 | Peak area normalized | female | Pre-diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 3052517 | Peak area normalized | female | Diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 3116298 | Peak area normalized | male | Pre-diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 3126798 | Peak area normalized | male | Diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 3262484 | Peak area normalized | female | Pre-diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 3284131 | Peak area normalized | female | Diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 3405041 | Peak area normalized | male | Pre-diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 3473075 | Peak area normalized | female | Diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 3676506 | Peak area normalized | female | Pre-diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 3709595 | Peak area normalized | male | Diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 3776176 | Peak area normalized | male | Normoglycemic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 3932456 | Peak area normalized | male | Diabetic | no neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 3975199 | Peak area normalized | female | Pre-diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 4039401 | Peak area normalized | male | Pre-diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 4879518 | Peak area normalized | male | Diabetic | Neuropathy |
| Reversed phase NEGATIVE ION MODE | 3-METHYL-2-OXOPENTANOIC ACID (M-H)- | 5226042 | Peak area normalized | male | Diabetic | no neuropathy |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|